ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,302Medicare Part D Prescriptions Filled, Including Refills

Rank: 114 out of 387

$564K Total Retail Price of All Prescriptions

Rank: 118 out of 387

438 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
28% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Oklahoma
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 438 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

19% of this provider’s 438 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

2% of this provider’s 8,297 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Oklahoma
SIMVASTATIN 560 500 1 5
HYDROCODONE-ACETAMINOPHEN 415 313 S3 2 1
LISINOPRIL 283 265 3 3
FUROSEMIDE 273 252 4 7
OMEPRAZOLE 268 249 5 4
METFORMIN HCL 247 218 6 8
AMLODIPINE BESYLATE 219 207 7 6
LEVOTHYROXINE SODIUM 206 193 8 2
WARFARIN SODIUM 145 129 9 17
CARVEDILOL 142 121 10 21
METOPROLOL TARTRATE 130 125 11 11
METOPROLOL SUCCINATE 125 102 12 18
LISINOPRIL-HYDROCHLOROTHIAZIDE 122 107 13 30
MELOXICAM 118 99 14 22
ZOLPIDEM TARTRATE 109 93 15 16
GABAPENTIN 106 87 16 10
PAROXETINE HCL 106 102 16 52
POTASSIUM CHLORIDE 104 99 18 9
HYDROCHLOROTHIAZIDE 103 96 19 12
FLUTICASONE PROPIONATE 90 77 20 29
POLYETHYLENE GLYCOL 3350 89 89 21 57
ATORVASTATIN CALCIUM 87 86 22 13
AMITRIPTYLINE HCL 86 72 R 23 62
TAMSULOSIN HCL 84 84 24 32
CLOPIDOGREL 84 73 24 25
TRAMADOL HCL 83 83 26 14
LOSARTAN-HYDROCHLOROTHIAZIDE 81 64 27 65
HYDRALAZINE HCL 81 69 27 94
CITALOPRAM HBR 80 76 29 19
DONEPEZIL HCL 80 80 29 27
ATENOLOL 80 79 29 20
LOSARTAN POTASSIUM 78 59 32 24
NAMENDA 73 73 33 35
PHENYTOIN SODIUM EXTENDED 72 60 34 107
ALLOPURINOL 70 63 35 28
SERTRALINE HCL 65 63 36 23
NAPROXEN 65 63 36 89
JANUVIA 65 42 36 60
SINGULAIR 62 62 39 83
ALENDRONATE SODIUM 62 62 39 31
GLIPIZIDE 60 49 41 63
DIOVAN HCT 59 59 42 74
CRESTOR 58 56 43 34
FINASTERIDE 57 55 44 95
LOVASTATIN 56 55 45 36
BUSPIRONE HCL 54 51 46 121
TORSEMIDE 53 48 47 132
IBUPROFEN 52 48 48 85
PRAVASTATIN SODIUM 52 47 48 15
PLAVIX 52 46 48 39
ISOSORBIDE MONONITRATE ER 51 51 51 59
PROAIR HFA 51 35 51 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 29, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.